Experimental kidney cancer drug trial halted early

NCT ID NCT04895748

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination with other drugs, but the trial was terminated early, so we have limited information on its safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DFF332 (a drug that targets HIF2α protein)
What this could lead to: If it worked, DFF332 might offer a new way to slow or stop certain kidney cancers by blocking a protein that helps tumors grow.
What could go wrong: This was a very early (phase 1) trial that was terminated, meaning it was stopped before completion. It involved only 40 people, so any benefits or risks are not well understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary leiomyomatosis and renal cell cancer hereditary pheochromocytoma-paraganglioma nonpapillary renal cell carcinoma paraganglioma pheochromocytoma renal cell adenocarcinoma renal cell carcinoma von Hippel-Lindau disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, RENAL CELL

Contacts and locations

Locations

City of Hope National Medical

Duarte, California, 91010, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloane Ketterin Cancer Ctr

New York, New York, 10065, United States
Novartis Investigative Site

Brno, 656 53, Czechia
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Koto Ku, Tokyo, 1358550, Japan
Novartis Investigative Site

Singapore, 119228, Singapore
Novartis Investigative Site

Barcelona, 08035, Spain
Uni Of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
WA Uni School Of Med

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.